Search research articles
Contact Us
Filters
Showing results (31-40 of 92) with videos related to
Page
of 10
Sort By:
Translational Oncology
|
May 19, 2020
Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain
Jose A Lopez-Martin, Ana Arance Fernández, Juan José Ríos-Martín, et al.
Cancer Research
|
May 11, 2017
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Aleix Prat, Alejandro Navarro, Laia Paré, et al.
Cancers
|
June 2, 2021
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
Victoria G Atkinson, Pietro Quaglino, Massimo Aglietta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Clinical Pharmacokinetics
|
June 12, 2026
Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation
Arnau Torrent-Rodríguez, Carla Bastida, Esther Carcelero San Martín, et al.
Cancers
|
January 11, 2025
Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse
Sergio Martinez-Recio, Maria Alejandra Molina-Pérez, Eva Muñoz-Couselo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Caroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Plos One
|
November 12, 2024
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study
Graham Cohen, Bernardo Rapoport, Sze W Chan, et al.
American Journal of Clinical Dermatology
|
October 8, 2024
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
Laurent Mortier, Lisa Villabona, Ben Lawrence, et al.
Future Oncology (London, England)
|
June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF
Reinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 92) with videos related to
Sort By:
Page
of 10
Translational Oncology
|
May 19, 2020
Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain
Jose A Lopez-Martin, Ana Arance Fernández, Juan José Ríos-Martín, et al.
Cancer Research
|
May 11, 2017
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Aleix Prat, Alejandro Navarro, Laia Paré, et al.
Cancers
|
June 2, 2021
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
Victoria G Atkinson, Pietro Quaglino, Massimo Aglietta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Clinical Pharmacokinetics
|
June 12, 2026
Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation
Arnau Torrent-Rodríguez, Carla Bastida, Esther Carcelero San Martín, et al.
Cancers
|
January 11, 2025
Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse
Sergio Martinez-Recio, Maria Alejandra Molina-Pérez, Eva Muñoz-Couselo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Caroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Plos One
|
November 12, 2024
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study
Graham Cohen, Bernardo Rapoport, Sze W Chan, et al.
American Journal of Clinical Dermatology
|
October 8, 2024
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
Laurent Mortier, Lisa Villabona, Ben Lawrence, et al.
Future Oncology (London, England)
|
June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF
Reinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Page
of 10